Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-33 (canceled)

34 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound ~~or salt of claim 1 to the animal~~of the formula (I):



(I)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_1 is selected from the group consisting of:

-alkenyl;

-aryl; and

$-R_4$–aryl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-$CO\text{-}N(R_3)_2$;

-$CO\text{-}C_{1\text{-}10}$ alkyl;

-$CO\text{-}O\text{-}C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each R_3 is independently H or $C_{1\text{-}10}$ alkyl;

Y is –O– or $–S(O)_{0\text{-}2}–$;

n is 0; and

each R present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

35 (canceled)

36 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound ~~or salt of claim 11 to the animal~~of the formula (II):



(II)

wherein X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_{10} is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

n is 0;

Y is –O– or –$S(O)_{0-2}$-;

each R_3 is independently H or C_{1-10} alkyl; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

37-39 (canceled)

40 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound ~~or salt of claim 21 to the animal~~of the formula (III):



(III)

wherein: X is –CHR_3-, -CHR_3-alkyl-, or –CHR_3-alkenyl-;

R_1 is selected from the group consisting of:

-aryl;

-alkenyl; and

-R_4–aryl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

- alkyl-Y- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

R_4 is alkyl or alkenyl, which may be interrupted by one or more –O– groups;

each R_3 is independently H or C_{1-10} alkyl;

Y is –O– or –$S(O)_{0-2}$-;

n is 0; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

41-45 (canceled)

46 (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (IV):



(IV)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_{10} is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

-alkyl-Y- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-$CO\text{-}N(R_3)_2$;

-$CO\text{-}C_{1\text{-}10}$ alkyl;

-$CO\text{-}O\text{-}C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or $C_{1\text{-}10}$ alkyl;

Y is -O- or - $S(O)_{0\text{-}2}$-;

n is 0; and

each R present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

47 (new) A method of inducing cytokine biosynthesis in an animal comprising administering a compound of the formula (IV):



(IV)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_{10} is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

-alkyl-Y- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

-CO-C_{1-10} alkyl;

-CO-O-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or C_{1-10} alkyl;

Y is -O- or - $S(O)_{0-2}$-;

n is 0; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, to the animal in an amount effective for cytokine induction.

48 (new) The method of claim 47 wherein the cytokine is IFN-α.

49 (new) A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (IV):



(IV)

wherein: X is –CHR_3-, -CHR_3-alkyl-, or –CHR_3-alkenyl-;

R_{10} is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

-alkyl-Y- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

$-CO-O-C_{1-10}$ alkyl;

$-N_3$;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or C_{1-10} alkyl;

Y is -O- or - $S(O)_{0-2}$-;

n is 0; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

50 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (IV):



(IV)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

R_{10} is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

-alkyl-Y- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

$-CO-O-C_{1-10}$ alkyl;

$-N_3$;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or C_{1-10} alkyl;

Y is -O- or - $S(O)_{0-2}$-;

n is 0; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.